C12P9/00

CELL-FREE PRODUCTION OF GERANYL PYROPHOSPHATE FROM GLYCEROL IN A CELL-FREE MANUFACTURING SYSTEM
20250207160 · 2025-06-26 ·

Geranyl pyrophosphate (GPP) is a key intermediate molecule in the bioproduction of thousands of natural products. Currently, natural products are either cultivated from plants, synthesized via complex chemical synthesis strategies, or through cell-based factories also known as biofoundries. However, in order to replicate the process in a cell free environment, numerous enzymes and cofactors must be utilized making this approach costly and unviable. In order to make this process viable, a new approach was needed that uses fewer enzymes and cofactors. As described herein, the present invention demonstrates that it is possible to create GPP from glycerol through a short and concise biosynthetic pathway outside of the cell.

METHODS FOR MAKING L-GLUFOSINATE
20250250596 · 2025-08-07 ·

Methods for the production of L-glufosinate (also known as phosphinothricin or (S)-2-amino-4-(hydroxy(methyl)phosphonoyl)butanoic acid) are provided. The methods comprise a two-step process. The first step involves the oxidative deamination of D-glufosinate to PPO (2-oxo-4-(hydroxy(methyl)phosphinoyl)butyric acid). The second step involves the specific amination of PPO to L-glufosinate, using an amine group from one or more amine donors. By combining these two reactions, the proportion of L-glufosinate in a mixture of L-glufosinate and D-glufosinate can be substantially increased.

METHODS FOR MAKING L-GLUFOSINATE
20250250596 · 2025-08-07 ·

Methods for the production of L-glufosinate (also known as phosphinothricin or (S)-2-amino-4-(hydroxy(methyl)phosphonoyl)butanoic acid) are provided. The methods comprise a two-step process. The first step involves the oxidative deamination of D-glufosinate to PPO (2-oxo-4-(hydroxy(methyl)phosphinoyl)butyric acid). The second step involves the specific amination of PPO to L-glufosinate, using an amine group from one or more amine donors. By combining these two reactions, the proportion of L-glufosinate in a mixture of L-glufosinate and D-glufosinate can be substantially increased.

ISOLATED OR ENGINEERED POLYPEPTIDES, MICROORGANISMS AS WELL AS METHOD FOR SYNTHESIZING POLYPHENOLIC PHYTOCHEMICALS PHOSPHATE DERIVATIVE USING THE POLYPEPTIDES OR MICROORGANISMS
20250257336 · 2025-08-14 ·

The present invention provides an isolated or engineered polypeptide, a microorganism comprising a nucleic acid sequence encoded by the polypeptide, and a method for synthesizing a polyphenolic phytochemicals phosphate derivative using the polypeptide or the microorganism. The polypeptide having a homologous protein sequence that is more than 70% identical to the polyphenol phosphorylation synthetase (SEQ ID NO: 13) comprises a conserved domain which sequentially comprises: an ATP-binding domain, which includes active catalytic sites of Lys27, Arg102, and Glu282; a substrate-binding domain, which includes a conserved motif of DDHHFYIDAMLDAKAR (SEQ ID NO: 14), and includes active catalytic sites of Asp627, His629, and His630; and a phosphorylated histidine catalytic domain, which includes His795 based on SEQ ID NO: 13.

ISOLATED OR ENGINEERED POLYPEPTIDES, MICROORGANISMS AS WELL AS METHOD FOR SYNTHESIZING POLYPHENOLIC PHYTOCHEMICALS PHOSPHATE DERIVATIVE USING THE POLYPEPTIDES OR MICROORGANISMS
20250257336 · 2025-08-14 ·

The present invention provides an isolated or engineered polypeptide, a microorganism comprising a nucleic acid sequence encoded by the polypeptide, and a method for synthesizing a polyphenolic phytochemicals phosphate derivative using the polypeptide or the microorganism. The polypeptide having a homologous protein sequence that is more than 70% identical to the polyphenol phosphorylation synthetase (SEQ ID NO: 13) comprises a conserved domain which sequentially comprises: an ATP-binding domain, which includes active catalytic sites of Lys27, Arg102, and Glu282; a substrate-binding domain, which includes a conserved motif of DDHHFYIDAMLDAKAR (SEQ ID NO: 14), and includes active catalytic sites of Asp627, His629, and His630; and a phosphorylated histidine catalytic domain, which includes His795 based on SEQ ID NO: 13.

Method for producing selenoneine
12398411 · 2025-08-26 · ·

The purpose of the present invention is to provide a method for producing selenoneine that allows production of selenoneine at higher yields, even if an inorganic selenium compound is used as a selenium compound. This purpose can be achieved by a method for producing selenoneine, comprising the step of applying histidine and a selenium compound to a transformant to obtain selenoneine, wherein the transformant has at least one gene selected from the group consisting of a SatA gene, a CysB gene and a MetR gene, and an EgtA gene inserted therein and can overexpress the inserted genes.

Method for producing selenoneine
12398411 · 2025-08-26 · ·

The purpose of the present invention is to provide a method for producing selenoneine that allows production of selenoneine at higher yields, even if an inorganic selenium compound is used as a selenium compound. This purpose can be achieved by a method for producing selenoneine, comprising the step of applying histidine and a selenium compound to a transformant to obtain selenoneine, wherein the transformant has at least one gene selected from the group consisting of a SatA gene, a CysB gene and a MetR gene, and an EgtA gene inserted therein and can overexpress the inserted genes.

Krill oil composition enriched in LPC-DHA and LPC-EPA

The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.

Krill oil composition enriched in LPC-DHA and LPC-EPA

The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.

METHOD FOR PREPARING KETO ACIDS, AND USE OF SAME IN PREPARATION OF AMINO ACIDS OR AMINO ACID DERIVATIVES
20250305012 · 2025-10-02 ·

In a method for preparing a keto acid, an enzymatic reaction is carried out by using glycine and an alcoholic organic substance as substrates; the alcoholic organic substance is converted into an aldehyde organic substance, glycine and the aldehyde organic substance are converted into a -hydroxy--amino acid, and then the -hydroxy--amino acid is converted into a keto acid. The preparation method for a keto acid can also be used in the preparation of amino acids. The number of enzymes used is much less than that of enzymes used in a natural synthesis route, so that the production cost is low. An artificial metabolism platform for keto acids is established and can produce multiple important keto acids, such as phenylpyruvic acid, 4-methyl-2-oxopentanoic acid, pyruvic acid and 2-oxo-butyric acid.